logo

For the Inventor, By the Inventor

Visp, Switzerland

Thomas Meul

This inventor holds 30 USPTO granted patents and 2 EPO patents, primarily in Chiral Chemistry. Top assignees: Lonza Inc., Drug'on Pharma Switzerland Ag. Active years: 1986-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Meul. Retrieved from https://idiyas.com/inventor/thomas-meul

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30

% Patents Active = 96.7

 

Average Co-Inventor Count = 1.3

ph-index = 4

Forward Citations = 52(Granted Patents)


Location History:

  • Canton Valais, CH (1989)
  • Visp (Canton Valais), CH (1989)
  • Visp (Kanton Wallis), CH (1989)
  • Visp, CH (1986 - 2020)

Company Filing History:

goldMedal29 out of 612 
 
Lonza Inc.
 patents
silverMedal1 out of 1 
 
Drug'on Pharma Switzerland Ag
 patent

Years Active: 1986-2020

Loading Chart...
Loading Chart...
Areas of Expertise:
Chiral Biotin Precursors
Optically-Active Compounds
Tetramic Acids
Racemates Resolution
Salicyloyl-Carnitine
Dimethylcyclopropanecarboxylic Acid
4-Alkoxy-3-Pyrrolin-2-Ones
Thiotetronic Acid
5-Alkyl Tetramic Acids
Acetylsalicyloyl-L-Carnitine
4-Hydroxy-2-Oxo-Pyrrolidin-1-Yl Acetamide
30 patents (USPTO):Explore Patents
1. 10723691 - Process for preparing salicyloyl-L-carnitine hydrochloride (2020-07-28),
2. 6462229 - Process for the preparation of (-)-&agr;-(difluoromethyl)ornithine-monohydrochloride monohydrate (2002-10-08),
3. 5352801 - Process for the production of optically-active (1994-10-04),
4. 5286650 - Process for the production of optically-active (1994-02-15),
5. 5258523 - Process for the production of 2-aryl-2H-1,2,3-triazoles (1993-11-02),
6. 5243070 - Process for resolution of racemates of (1993-09-07),
7. 5227514 - Salicyloyl-carnitine and process for its production (1993-07-13),
8. 5227513 - Acetylsalicyloyl-L-carnitine and process for its production (1993-07-13),
9. 5166417 - Process for resolution of racemates of (1992-11-24),
10. 5149869 - Process for the production of dimethylcyclopropanecarboxylic acid (1992-09-22),
11. 5093503 - Process for the production of thiotetronic acid (1992-03-03),
12. 5008402 - Process for production of 5-alkyl tetramic acids (1991-04-16),
13. 4997957 - Process for the production of thiotetronic acid (1991-03-05),
14. 4983743 - 5-alkyl tetramic acids (1991-01-08),
15. 4931570 - Process for the production of 4-alkoxy-2(5H) thiophenones (1990-06-05),

Title: The Innovative Contributions of Thomas Meul in the Pharmaceutical Field

Introduction

Thomas Meul, located in Visp, Switzerland, is an accomplished inventor with a remarkable portfolio of 30 patents. His work primarily focuses on innovative processes for synthesizing pharmaceutical compounds, demonstrating a significant contribution to the field of medicinal chemistry.

Latest Patents

Among his latest patents is the process for preparing salicyloyl-L-carnitine hydrochloride. This invention involves a method for synthesizing 3-(2-hydroxybenzoyloxy)-4-(trimethylammonio)butyrobetaine hydrochloride. The process comprises reacting 3-hydroxy-4-(trimethylammonio)butyrobetaine or a salt with a 2-alkoxybenzoyl chloride, where R can be benzyl or branched C3-C6 alkyl groups. Another notable patent is for the preparation of (-)-α-(difluoromethyl)ornithine-monohydrochloride monohydrate. This compound involves the separation of isomers using (-)-O,O’-di-p-toluoyl-L-tartaric acid, highlighting its role as an inhibitor of ornithine decarboxylase with potential pharmacological applications.

Career Highlights

Throughout his career, Thomas Meul has made significant strides in pharmaceutical innovation while working with leading companies such as Lonza Inc. and Drug'on Pharma Switzerland AG. His expertise in developing novel compounds has positioned him as a key player in the industry, contributing to advancements in therapeutic agents.

Collaborations

Thomas Meul has collaborated with notable professionals, including John McGarrity and Leander Tenud. These partnerships have fostered an environment of innovation, enabling the exchange of ideas and enhancing the scope of research within the pharmaceutical sector.

Conclusion

With his extensive patent portfolio and collaborative efforts, Thomas Meul continues to push the boundaries of pharmaceutical research. His inventions not only exemplify technical ingenuity but also promise to impact health care positively, paving the way for future advancements in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…